Expands Manufacturing of HIV Tests for International Markets MEDFORD, N.Y. , Oct. 17, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its manufacturing facility in Malaysia has been
MEDFORD, N.Y. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the closing of a $20 million term loan with an affiliate of Perceptive Advisors , one of the world’s leading
MEDFORD, N.Y. , Aug. 27, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the company plans to participate in two upcoming investor conferences.
MEDFORD, N.Y. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2019 . Recent Accomplishments & Highlights Achieved total revenue
MEDFORD, N.Y. , July 24, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the company plans to participate in the upcoming Canaccord Genuity Growth Conference in Boston, MA.
MEDFORD, N.Y. , July 24, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 2019 after the close of trading on Tuesday, August
MEDFORD, N.Y. , July 18, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care (POC) diagnostics company focused on infectious diseases, today announced that it has entered into a collaboration with Shire Human Genetic Therapies, Inc.
MEDFORD, N.Y. , June 27, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that is has obtained a CE mark for its DPP Zika/Dengue/Chikungunya multiplex test system.
MEDFORD, N.Y. , May 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Dengue System by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health
MEDFORD, N.Y. , May 01, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2019 . Recent Accomplishments & Highlights Achieved total revenue
Print Page